Design Validation of Senofilcon A With New UV-blocking Additive

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

253 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-01

Study Completion Date

2018-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 2-visit, multi-site, partially subject-masked, 2-arm parallel, controlled, randomized and dispensing trial. Subjects will be randomized to one of two study lenses for the entire duration of the study. The study lenses will be worn for a period of 2 weeks each in a bilateral fashion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Senofilcon A With New UV-blocker on a Neophyte Population

NCT03742271

Visual Acuity

COMPLETED NA

Visual Performance of Senofilcon A With and Without a New UV/HEV-filter

NCT05021081

Visual Performance

COMPLETED NA

Validation of Senofilcon A With New UV / HEV Filter

NCT05099380

Visual Acuity

COMPLETED NA

Clinical Performance of Senofilcon A Investigational Lens

NCT05300763

Visual Acuity

COMPLETED NA

Design Validation of Toric Contact Lenses in Senofilcon A With a Blue-Blocking Chromophore

NCT05778786

Visual Acuity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Visual Acuity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

senofilcon A TEST Lens

Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.

Group Type EXPERIMENTAL

senofilcon A TEST Lens

Intervention Type DEVICE

JJVC Investigational Contact Lens

senofilcon A CONTROL Lens

Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.

Group Type ACTIVE_COMPARATOR

senofilcon A CONTROL Lens

Intervention Type DEVICE

Acuvue Oasys

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

senofilcon A TEST Lens

JJVC Investigational Contact Lens

Intervention Type DEVICE

senofilcon A CONTROL Lens

Acuvue Oasys

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Potential subjects must satisfy all of the following criteria to be enrolled in the study:

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Between 18 and 49 (inclusive) years of age at the time of informed consent.
4. Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them when needed for near vision.
5. The subject is a current spherical soft contact lens wearer in both eyes with a minimum of 6 hours/day and 5 days/week wear time over the last 30 days by self-report.
6. Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week.
7. Subjects must own a wearable pair of distance spectacles.
8. The subject's vertex-corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D (inclusive) in each eye.
9. The subject's refractive cylinder must be 0.00 to -1.00 D (inclusive) in each eye.
10. The subject must have a spherocylindrical best corrected distance Snellen visual acuity of 20/25+3 or better in each eye.

Exclusion Criteria

* Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
2. Any active or ongoing systemic disease (e.g., Sjögren's Syndrome), infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis).
3. Subjects taking suspect oral medications for less than one year.
4. Any prescribed or over the counter (OTC) ocular medication.
5. Any known hypersensitivity or allergic reaction to Optifree® PureMoist® multi-purpose care solution or Eye-Cept® rewetting drop solution.
6. Toric, extended wear, monovision or multi-focal contact lens correction.
7. Any previous or planned (during the course of the study) ocular surgery (e.g., PRK, LASIK, etc.).
8. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
9. Participation in clinical trials involving the Test lens within 3 months prior to study enrollment.
10. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
11. Binocular vision abnormality or strabismus by self-report or prior medical history.
12. History of recurrent corneal erosions, herpetic keratitis, or pathological dry eye.
13. Any active ocular allergies, infections or other ocular abnormalities (entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma) that the investigator determines may interfere with the outcomes of this study or otherwise contraindicate participation in the study.
14. Any Grade 2 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA Slit Lamp Classification Scale.
15. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar) within the past 3 years of otherwise successful contact lens wear.

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes